Use of an anti-reflux catheter to improve tumor targeting for holmium-166 radioembolization-a prospective, within-patient randomized study.

ABSTRACT:

Purpose

The objective of this study was to investigate whether the use of an anti-reflux catheter improves tumor targeting for colorectal cancer patients with unresectable, chemorefractory liver metastases (mCRC) treated with holmium-166 (¹⁶⁶Ho)-radioembolization.

Materials and methods

In this perspective, within-patient randomized study, left and right hepatic perfusion territories were randomized between infusion with a Surefire® anti-reflux catheter or a standard microcatheter. The primary outcome was the difference in tumor to non-tumor (T/N) activity distribution. Secondary outcomes included the difference in infusion efficiency, absorbed doses, predictive value of ¹⁶⁶Ho-scout, dose-response relation, and survival.

Results

Twenty-one patient

SUBMITTER: van Roekel C 

PROVIDER: S-EPMC8113291 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature